IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
Go back to IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx| BIO-RAD LABORATORIES (NYSE: BIO) | Delayed: 386.11 -1.79 (0.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $387.90 | 52 Week High | $174.02 | |||
| Open | $380.84 | 52 Week Low | $122.03 | |||
| Day High | $386.78 | P/E | 124.95 | |||
| Day Low | $376.20 | EPS | $3.09 | |||
| Volume | 112,951 | |||||
| (NASDAQ: IMDX) | Delayed: 4.13 +0.01 (0.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.12 | 52 Week High | $ | |||
| Open | $4.10 | 52 Week Low | $ | |||
| Day High | $4.18 | P/E | N/A | |||
| Day Low | $3.99 | EPS | $ | |||
| Volume | 183,525 | |||||
